KNSA
Kiniksa Pharmaceuticals International, plc Class A · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website kiniksa.com
- Employees(FY) 220
- ISIN GB00BRXB0C07
Performance
-6.84%
1W
+3.4%
1M
+26.48%
3M
+23.54%
6M
+42.13%
YTD
+44.27%
1Y
Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Technical Analysis of KNSA 2024-09-06
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-08-28 16:01
- 2024-08-28 04:01
- 2024-08-05 09:55
- 2024-08-05 06:50
- 2024-08-02 07:19
- 2024-07-26 12:00
- 2024-07-26 09:06
- 2024-07-26 08:50
- 2024-07-26 08:43
- 2024-07-26 08:34
- 2024-07-24 09:07
- 2024-07-23 10:30
- 2024-07-23 08:09
- 2024-07-23 07:30
- 2024-07-22 20:35
- 2024-07-22 19:30
- 2024-07-16 16:01
- 2024-07-16 04:01
- 2024-07-12 11:57
- 2024-07-09 08:00
- 2024-07-08 20:00
- 2024-07-08 20:00
- 2024-07-01 05:22
Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf(MT Newswires)
- 2024-06-26 09:18
- 2024-06-25 17:57
- 2024-06-24 10:47
- 2024-06-24 08:00
- 2024-06-23 20:00
- 2024-06-17 08:30
- 2024-06-16 20:30
Page 1 of 7
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.